Aethlon Medical Announces Expanded Access To Hemopurifier(R) Therapy
Published Thursday, August 09, 2012 by Paul Archie
Aethlon Medical, Inc. (OTC:AEMD) today announced the expanded availability of their uniquely effective Hepatitis C therapy, the Hemopurifier®. This advanced blood filtration system works in conjunction with the currently available standard-of-care drug treatment, peginterferon + ribavarin (PR) from Roche Holding AG (OTC:RHHBY), and has been shown to greatly increase the efficacy of that treatment.
Unlike other complimentary drug therapies like sovaprevir from Achillion Pharmaceuticals (NASDAQ:ACHN), the Hemopurifier® has no additional toxicity concerns (the biggest problem with compounding drug treatments) and actually works outside of the body. Whereas sovaprevir has been shown to be effective in combination with 24 weeks of PR treatment, Aethlon’s system has been shown to reach an undetectable viral load in as little as seven days.
The Hemopurifier® has been submitted to the U.S. Food and Drug Administration for an investigational device exemption. The therapy has previously been offered in India, to Indian citizens, with excellent results. This announcement signals the expansion of that offering to the global pool of HCV patients and is a big step in the product’s commercialization process.